Clinical Trial

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-11-17; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-21
Trial Details
NCT Number NCT07241390
Lead Sponsor Eli Lilly and Company
Conditions Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Enrollment 7,140 participants
Start Date 2025-12-01
Primary Completion 2031-08 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-06